Research & Regulatory News

Orforglipron: Reported Side Effects and Tolerability

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

The most commonly reported adverse effects of orforglipron are gastrointestinal: nausea, constipation, diarrhoea, vomiting, dyspepsia and abdominal pain. This profile is characteristic of GLP-1 receptor agonism generally rather than specific to orforglipron, and follows directly from how the receptor affects gastric emptying and satiety signalling.

Key facts

Most common effects
Nausea, constipation, diarrhoea, vomiting
Also reported
Dyspepsia, abdominal pain
Nature
Class effect across GLP-1 agonists
Mechanistic cause
Delayed gastric emptying, area postrema signalling
Typical pattern
Dose-related, most pronounced during escalation
Reporting route (UK)
MHRA Yellow Card scheme

Why the effects are gastrointestinal

GLP-1 receptor agonism slows gastric emptying and acts on brainstem structures including the area postrema, which is central to both satiety and nausea. The therapeutic effect and the principal adverse effect therefore arise from the same mechanism rather than from an off-target action. This is why the profile is so consistent across the class regardless of chemistry. Peptide or not, injected or oral.

How this compares across the class

Gastrointestinal events dominate for every incretin compound reported to date. In retatrutide's TRIUMPH-1, nausea was reported by 42.4% on the 12 mg arm against 14.8% on placebo, and diarrhoea by 32.0% against 13.5%. Multi-agonists engaging more receptors generally report higher rates than GLP-1-only compounds, which is one of the trade-offs that comes with larger effect size.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Discontinuation is the figure that matters

Incidence of an adverse event says less than how many people stopped because of one. TRIUMPH-1 reported 11.3% discontinuation due to adverse events on 12 mg against 4.9% on placebo. That number is frequently absent from summaries, and it is the one that connects tolerability to real-world outcome. A compound nobody can stay on does not deliver its trial result.

What the tablet format does and does not change

Being a tablet with no absorption enhancer removes the dosing conditions oral semaglutide carries, and removes injection-site reactions entirely. It does not change the gastrointestinal profile, because that follows from receptor pharmacology rather than route. A more convenient tablet is not automatically a better-tolerated drug.

Reporting suspected adverse effects in the UK

The MHRA operates the Yellow Card scheme for reporting suspected adverse drug reactions, defective medicines and falsified products. Reports can be submitted by healthcare professionals and by patients directly. It is also the correct route for reporting a suspected counterfeit GLP-1 product.

Frequently asked questions

Are orforglipron's side effects different because it is a tablet?

No. The gastrointestinal profile follows from GLP-1 receptor pharmacology, not from route. The tablet removes dosing conditions and injection-site reactions, not nausea.

Why do multi-agonists report higher rates?

Engaging more receptors increases both the therapeutic effect and the mechanism-linked adverse effects. Larger effect sizes have consistently come with higher gastrointestinal burden.

How do I report a side effect in the UK?

Through the MHRA Yellow Card scheme, which accepts reports from healthcare professionals and from patients directly.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.